Many drugs work by targeting proteins. Biologic medicines showed that proteins can be made into therapies too—in some cases using proteins from the body. Juvena Therapeutics works with a type of ...
A study co-led by UCLA scientists has found targeting a protein called endocan and its related signaling pathway could be a promising new approach for treating glioblastoma, an aggressive and lethal ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, No. 32 (August 10, 2021), pp. 1-11 (11 pages) Family with sequence similarity 20C (Fam20C), the major protein ...
In the world of protein degradation, sometimes a spanner in the works isn’t an inconvenience but the desired result. Paris-based Enodia Therapeutics has launched out of France’s Pasteur Institute and ...
Autophagy and lysosomal pathways orchestrate unconventional secretion of Parkinson’s disease protein
Oxidative stress induced by 6-OHDA stimulates autophagy flux, which enhances STX17-mediated autolysosome formation, leading to the degradation of autophagosomal contents. However, in response to ...
Medical Device Network on MSN
Enodia raises seed funding to advance protein degradation platform
Enodia employs a large chemical space of inhibitors and a purpose-built library of signal-peptide cell lines.
When targeting problem proteins involved in causing or spreading disease, a drug will often clog up a protein's active site so it can't function and wreak havoc. New strategies for dealing with these ...
Cell adhesion molecules (CAMS), i.e., laminin-1 or N-cadhedrin Adhesion and attractant Allow cells to grow along the surfaces of other cells (such as using pioneering axons for subsequent axons) ...
A study co-led by UCLA scientists has found targeting a protein called endocan and its related signaling pathway could be a promising new approach for treating glioblastoma, an aggressive and lethal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback